JP2021513844A5 - - Google Patents
Info
- Publication number
- JP2021513844A5 JP2021513844A5 JP2020543351A JP2020543351A JP2021513844A5 JP 2021513844 A5 JP2021513844 A5 JP 2021513844A5 JP 2020543351 A JP2020543351 A JP 2020543351A JP 2020543351 A JP2020543351 A JP 2020543351A JP 2021513844 A5 JP2021513844 A5 JP 2021513844A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- occupied
- conjugated
- item
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023067166A JP2023089195A (ja) | 2018-02-15 | 2023-04-17 | グリピカン３抗体およびそのコンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631353P | 2018-02-15 | 2018-02-15 | |
| US62/631,353 | 2018-02-15 | ||
| PCT/US2019/018182 WO2019161174A1 (en) | 2018-02-15 | 2019-02-15 | Glypican 3 antibodies and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067166A Division JP2023089195A (ja) | 2018-02-15 | 2023-04-17 | グリピカン３抗体およびそのコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513844A JP2021513844A (ja) | 2021-06-03 |
| JP2021513844A5 true JP2021513844A5 (enExample) | 2022-02-22 |
| JP7402807B2 JP7402807B2 (ja) | 2023-12-21 |
Family
ID=67620075
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543351A Active JP7402807B2 (ja) | 2018-02-15 | 2019-02-15 | グリピカン３抗体およびそのコンジュゲート |
| JP2023067166A Pending JP2023089195A (ja) | 2018-02-15 | 2023-04-17 | グリピカン３抗体およびそのコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067166A Pending JP2023089195A (ja) | 2018-02-15 | 2023-04-17 | グリピカン３抗体およびそのコンジュゲート |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11819553B2 (enExample) |
| EP (1) | EP3752534A4 (enExample) |
| JP (2) | JP7402807B2 (enExample) |
| KR (1) | KR20200121317A (enExample) |
| CN (1) | CN111712520A (enExample) |
| AR (1) | AR114112A1 (enExample) |
| AU (1) | AU2019220700A1 (enExample) |
| CA (1) | CA3090251A1 (enExample) |
| IL (1) | IL276514B2 (enExample) |
| MX (1) | MX2020008030A (enExample) |
| SG (1) | SG11202007073SA (enExample) |
| TW (1) | TWI851552B (enExample) |
| WO (1) | WO2019161174A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI851531B (zh) | 2016-08-09 | 2024-08-11 | 美商思進公司 | 具有改善之生理化學性質之具自我穩定連接子之藥物結合物 |
| AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| CA3170023A1 (en) * | 2020-02-27 | 2021-09-02 | Nanjing Legend Biotech Co., Ltd. | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
| AU2021251875A1 (en) | 2020-04-10 | 2022-11-03 | Seagen Inc. | Charge variant linkers |
| MX2022013920A (es) * | 2020-05-07 | 2022-11-30 | Phanes Therapeutics Inc | Anticuerpos anti-antigeno asociado con tumor y usos de los mismos. |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| CN112921005B (zh) * | 2021-04-14 | 2023-07-07 | 中国农业科学院兰州兽医研究所 | 一株杂交瘤细胞株及其产生的犬细小病毒vp2蛋白单克隆抗体和应用 |
| AU2022283467A1 (en) | 2021-05-28 | 2023-12-07 | Seagen Inc. | Anthracycline antibody conjugates |
| WO2023023354A2 (en) * | 2021-08-19 | 2023-02-23 | Adicet Therapeutics, Inc. | Methods for detection of membrane bound glypican-3 |
| WO2023045151A1 (en) * | 2021-09-24 | 2023-03-30 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against gpc3 and uses thereof |
| WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
| WO2023207475A1 (zh) * | 2022-04-24 | 2023-11-02 | 昱言科技(北京)有限公司 | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 |
| EP4591887A1 (en) * | 2022-09-22 | 2025-07-30 | Lepu Biopharma Co., Ltd. | Gpc3 antibody-drug conjugate and use thereof |
| CN119968398A (zh) * | 2022-11-28 | 2025-05-09 | 四川科伦博泰生物医药股份有限公司 | 靶向gpc3的抗体及其用途 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| CN119424671A (zh) * | 2023-08-01 | 2025-02-14 | 上海新理念生物医药科技有限公司 | 含糖基吡啶型连接子的抗体药物偶联物 |
| AR134171A1 (es) | 2023-10-24 | 2025-12-10 | Seagen Inc | Compuestos quimioterapéuticos y métodos de uso |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| KR100953520B1 (ko) | 2001-06-22 | 2010-04-21 | 츄가이 세이야꾸 가부시키가이샤 | 항글리피칸 3항체를 포함하는 항암제 |
| WO2004022597A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| SI1674111T1 (sl) * | 2004-07-09 | 2011-02-28 | Chugai Pharmaceutical Co Ltd | Protitelo proti glipikanu 3 |
| JP2013511994A (ja) * | 2009-11-30 | 2013-04-11 | バイオテスト・アクチエンゲゼルシヤフト | 全身性エリテマトーデス（ｓｌｅ）を治療するためのヒト化抗ｉｌ−１０抗体 |
| JP6827319B2 (ja) * | 2014-05-08 | 2021-02-10 | 中外製薬株式会社 | Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤 |
| WO2015179658A2 (en) * | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| EP2963057A1 (en) * | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| FI3900742T3 (fi) * | 2014-09-11 | 2024-08-16 | Seagen Inc | Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen |
| WO2017181109A1 (en) * | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
| US20170326249A1 (en) * | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses |
| AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
-
2019
- 2019-02-14 AR ARP190100366A patent/AR114112A1/es not_active Application Discontinuation
- 2019-02-15 JP JP2020543351A patent/JP7402807B2/ja active Active
- 2019-02-15 SG SG11202007073SA patent/SG11202007073SA/en unknown
- 2019-02-15 WO PCT/US2019/018182 patent/WO2019161174A1/en not_active Ceased
- 2019-02-15 EP EP19755133.6A patent/EP3752534A4/en not_active Withdrawn
- 2019-02-15 US US16/970,095 patent/US11819553B2/en active Active
- 2019-02-15 CN CN201980012811.4A patent/CN111712520A/zh active Pending
- 2019-02-15 TW TW108105041A patent/TWI851552B/zh active
- 2019-02-15 AU AU2019220700A patent/AU2019220700A1/en not_active Abandoned
- 2019-02-15 CA CA3090251A patent/CA3090251A1/en active Pending
- 2019-02-15 KR KR1020207025196A patent/KR20200121317A/ko not_active Ceased
- 2019-02-15 MX MX2020008030A patent/MX2020008030A/es unknown
- 2019-02-15 IL IL276514A patent/IL276514B2/en unknown
-
2023
- 2023-04-17 JP JP2023067166A patent/JP2023089195A/ja active Pending
- 2023-10-13 US US18/486,335 patent/US20240173427A1/en active Pending